- Conditions
- Uveitis, Posterior, Uveitis, Intermediate
- Interventions
- V404
- Drug
- Lead sponsor
- Forsight Vision4
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 5
- States / cities
- Golden, Colorado • Atlanta, Georgia • Omaha, Nebraska + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 69
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non-Infectious Uveitis
- Interventions
- FAI insert, Sham injection
- Drug
- Lead sponsor
- EyePoint Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 16
- States / cities
- Beverly Hills, California • Sacramento, California • Torrance, California + 13 more
- Conditions
- Uveitis, Posterior
- Interventions
- Fluocinolone Acetonide Intravitreal Implant 0.18 mg
- Drug
- Lead sponsor
- Alimera Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 23
- States / cities
- Fullerton, California • Glendale, California • Pasadena, California + 20 more
- Conditions
- Non-infectious Intermediate and Posterior Uveitis
- Interventions
- Methotrexate
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Uveitis, Intermediate Uveitis, Posterior Uveitis, Panuveitis
- Interventions
- Sirolimus (rapamycin)
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Uveitis, Posterior, Uveitis, Intermediate, Panuveitis
- Interventions
- Placebo, LX211
- Drug
- Lead sponsor
- Lux Biosciences, Inc.
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Chicago, Illinois + 16 more
- Conditions
- Non-Infectious Uveitis
- Interventions
- FAI Insert administered using the Mk II inserter, FAI Insert administered using the Mk I inserter
- Drug
- Lead sponsor
- EyePoint Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 6
- States / cities
- Colorado Springs, Colorado • Waltham, Massachusetts • Durham, North Carolina + 3 more
- Conditions
- Uveitis
- Interventions
- Sarilumab, Prednisone, Methotrexate, Folic/folinic acid, Placebo (for Sarilumab)
- Drug · Other
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 5
- States / cities
- Worcester, Massachusetts • Omaha, Nebraska • Slingerlands, New York + 2 more
- Conditions
- Anterior Uveitis, Posterior Uveitis, Panuveitis, Uveitis
- Interventions
- Not listed
- Lead sponsor
- The New York Eye & Ear Infirmary
- Other
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Uveitis, Posterior
- Interventions
- Retisert, Fluocinolone Acetonide Intravitreal Implant
- Device · Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 12 Years to 80 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Macular Edema, Cystoid, Uveitis
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1998 – 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Uveitis
- Interventions
- fluocinolone acetonide intraocular implant, oral corticosteroid with immunosuppressive agents as needed
- Drug
- Lead sponsor
- JHSPH Center for Clinical Trials
- Other
- Eligibility
- 13 Years and older
- Enrollment
- 255 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 21
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 16 more
- Conditions
- Non-infectious Uveitis
- Interventions
- AIN457, Placebo
- Biological · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 24
- States / cities
- Artesia, California • Beverly Hills, California • Atlanta, Georgia + 10 more
- Conditions
- Uveitis, Posterior, Uveitis, Intermediate, Panuveitis
- Interventions
- Acthar Gel
- Drug
- Lead sponsor
- Mallinckrodt
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 8
- States / cities
- Clearwater, Florida • Indianapolis, Indiana • Waltham, Massachusetts + 5 more
- Conditions
- Uveitis, Intermediate, Uveitis, Posterior
- Interventions
- Dexamethasone pellet
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Uveitis
- Interventions
- Izokibep, Placebo
- Drug
- Lead sponsor
- ACELYRIN Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 36
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 29 more
- Conditions
- Uveitis
- Interventions
- Daclizumab (Zenapax)
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Uveitis
- Interventions
- Daclizumab
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Non-infectious Uveitis
- Interventions
- AIN457, AIN 457
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 20
- States / cities
- Beverly Hills, California • Los Angeles, California • Sacramento, California + 16 more
- Conditions
- Non-Infectious Uveitis of the Posterior Segment of the Eye
- Interventions
- DE-109 440 μg
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Sacramento, California • Golden, Colorado + 10 more
- Conditions
- Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis, Non-infectious Pan Uveitis
- Interventions
- Brepocitinib
- Drug
- Lead sponsor
- Priovant Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Palo Alto, California • Pasadena, California + 12 more
- Conditions
- Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate
- Interventions
- Yutiq 0.18 MG Drug Implant, Sham Injection
- Drug · Other
- Lead sponsor
- Texas Retina Associates
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Plano, Texas
- Conditions
- Behcet Disease
- Interventions
- AIN457, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Arlington, Texas • Houston, Texas
- Conditions
- Non-infectious Intermediate and Posterior Uveitis
- Interventions
- Daclizumab
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland